Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Authors
Keywords
Clozapine, Risperidone, Olanzapine, Quetiapine, Aripiprazole
Journal
DRUGS
Volume 77, Issue 1, Pages 29-46
Publisher
Springer Nature
Online
2016-12-17
DOI
10.1007/s40265-016-0670-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current status of PET imaging in Huntington’s disease
- (2016) Gennaro Pagano et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pridopidine for the treatment of Huntington’s disease
- (2016) Kathleen M. Shannon EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dietary Guidelines for Americans—Eat Less Salt
- (2016) Aaron P. Frank et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Progression of motor subtypes in Huntington’s disease: a 6-year follow-up study
- (2016) M. Jacobs et al. JOURNAL OF NEUROLOGY
- A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
- (2016) Jose Luis López-Sendón Moreno et al. JOURNAL OF NEUROLOGY
- Advancing pharmacotherapy for treating Huntington’s disease: a review of the existing literature
- (2015) Sarah L Mason et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dopamine and Huntington’s disease
- (2015) Laetitia C Schwab et al. Expert Review of Neurotherapeutics
- Treating the whole body in Huntington's disease
- (2015) Jeffrey B Carroll et al. LANCET NEUROLOGY
- A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
- (2015) Ralf Reilmann et al. MOVEMENT DISORDERS
- Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
- (2015) Ferdinando Squitieri et al. Drug Design Development and Therapy
- Dopamine and Huntington’s disease
- (2015) Laetitia C Schwab et al. Expert Review of Neurotherapeutics
- A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
- (2015) Lars Wojtecki et al. Frontiers in Neurology
- Aripiprazole (ABILIFY MAINTENA®): A Review of Its Use as Maintenance Treatment for Adult Patients with Schizophrenia
- (2014) Matt Shirley et al. DRUGS
- Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)
- (2014) Erik van Duijn et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Chorea associated with Huntington's disease: To treat or not to treat?
- (2014) Joseph Jankovic et al. MOVEMENT DISORDERS
- Onset of Huntington's disease: Can it be purely cognitive?
- (2014) Jane S. Paulsen et al. MOVEMENT DISORDERS
- Determinants of functional disability in Huntington's disease: Role of cognitive and motor dysfunction
- (2014) Christopher A. Ross et al. MOVEMENT DISORDERS
- Treatment of Huntington Disease
- (2013) Aleksandar Videnovic Current Treatment Options in Neurology
- Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline
- (2013) Ralf Reilmann MOVEMENT DISORDERS
- A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease
- (2013) MOVEMENT DISORDERS
- Phenomenology and classification of dystonia: A consensus update
- (2013) Alberto Albanese et al. MOVEMENT DISORDERS
- Treatment of Huntington’s Disease
- (2013) Samuel Frank Neurotherapeutics
- Recent advances in the management of choreas
- (2013) Jean-Marc Burgunder Therapeutic Advances in Neurological Disorders
- Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature
- (2012) Jack J. Chen et al. CLINICAL THERAPEUTICS
- Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology
- (2012) M. J. Armstrong et al. NEUROLOGY
- Cognitive Impairment in Huntington Disease: Diagnosis and Treatment
- (2011) Jane S. Paulsen Current Neurology and Neuroscience Reports
- Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
- (2011) Joseph Jankovic et al. Expert Review of Neurotherapeutics
- Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
- (2011) Justo Garcia de Yebenes et al. LANCET NEUROLOGY
- Age, CAG repeat length, and clinical progression in Huntington's disease
- (2011) Adam Rosenblatt et al. MOVEMENT DISORDERS
- Pharmacologic approaches to the treatment of Huntington's disease
- (2011) Charles S. Venuto et al. MOVEMENT DISORDERS
- Assessment of involuntary choreatic movements in Huntington's disease-Toward objective and quantitative measures
- (2011) Ralf Reilmann et al. MOVEMENT DISORDERS
- Huntington's disease: a clinical review
- (2011) Raymund A.C. Roos Orphanet Journal of Rare Diseases
- The Physiology, Signaling, and Pharmacology of Dopamine Receptors
- (2011) J.-M. Beaulieu et al. PHARMACOLOGICAL REVIEWS
- Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders
- (2010) David R.P. Guay American Journal Geriatric Pharmacotherapy
- A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease
- (2010) Karl Kieburtz ARCHIVES OF NEUROLOGY
- Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
- (2010) Anders Lundin et al. CLINICAL NEUROPHARMACOLOGY
- Dopamine and Glutamate in Huntington's Disease: A Balancing Act
- (2010) Véronique M. André et al. CNS Neuroscience & Therapeutics
- Advances in the Pharmacological Management of Huntingtonʼs Disease
- (2010) Samuel Frank et al. DRUGS
- In vivo pharmacology of the dopaminergic stabilizer pridopidine
- (2010) Henrik Ponten et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Tardive dyskinesia and other movement disorders secondary to aripiprazole
- (2010) Maria Sierra Peña et al. MOVEMENT DISORDERS
- Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
- (2009) Samuel Frank BMC Neurology
- The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties
- (2009) Tino Dyhring et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A pilot study using nabilone for symptomatic treatment in Huntington's disease
- (2009) Adrienne Curtis et al. MOVEMENT DISORDERS
- Risperidone and the Treatment of Psychiatric, Motor, and Cognitive Symptoms in Huntington's Disease
- (2008) Kevin Duff et al. Annals of Clinical Psychiatry
- The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
- (2008) Alfonso Fasano et al. CLINICAL NEUROPHARMACOLOGY
- A Europe-wide assessment of current medication choices in Huntington's disease
- (2008) Josef Priller et al. MOVEMENT DISORDERS
- Falls and gait disturbances in Huntington's disease
- (2008) Yvette A.M. Grimbergen et al. MOVEMENT DISORDERS
- Health-related quality of life in Huntington's disease: Which factors matter most?
- (2008) Aileen K. Ho et al. MOVEMENT DISORDERS
- Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
- (2008) Livia Brusa et al. MOVEMENT DISORDERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started